___

Turnbaugh PJ, Ley RE, Hamady M, , et al. The human microbiome project. Nature 2007; 449: 804-810.

Shreiner AB, Kao JY, Young VB. The gut microbiome in health and in disease. Curr Opin Gastroenterol 2015; 31: 69-75.

Group NHW, Peterson J, Garges S, et al. The NIH Human Microbiome Project. Genome Res 2009; 19: 2317-2323.

Sirisinha S. The potential impact of gut microbiota on your health:Current status and future challenges. Asian Pac J Allergy Immunol 2016; 34: 249-264.

Conlan S, Kong HH, Segre JA. Species-level analysis of DNA sequence data from the NIH Human Microbiome Project. PLoS One 2012; 7: e47075.

Human Microbiome Project C. A framework for human microbiome research. Nature 2012; 486: 215-221.

Qin J, Li R, Raes J, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010; 464: 59-65.

Guaraldi F, Salvatori G. Effect of breast and formula feed- ing on gut microbiota shaping in newborns. Front Cell Infect Microbiol 2012; 2: 94.

Flint HJ, Scott KP, Duncan SH, et al. Microbial degradation of complex carbohydrates in the gut. Gut Microbes 2012; 3: 289-306.

Duncan SH, Flint HJ. Probiotics and prebiotics and health in ageing populations. Maturitas 2013; 75: 44-50.

Arumugam M, Raes J, Pelletier E, et al. Enterotypes of the human gut microbiome. Nature 2011; 473: 174-180.

Hebuterne X. Gut changes attributed to ageing: effects on intestinal microflora. Curr Opin Clin Nutr Metab Care 2003; 6: 49-54.

Patel PJ, Singh SK, Panaich S, et al. The aging gut and the role of prebiotics, probiotics, and synbiotics: A review. Journal of Clinical Gerontology and Geriatrics 2014; 5: 3-6.

Larsbrink J, Rogers TE, Hemsworth GR, et al. A discrete genetic locus confers xyloglucan metabolism in select human gut Bacteroidetes. Nature 2014; 506: 498-502.

Kim D, Yoo SA, Kim WU. Gut microbiota in autoimmuni- ty: potential for clinical applications. Arch Pharm Res 2016; 39: 1565-1576.

den Besten G, van Eunen K, Groen AK, et al. The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. J Lipid Res 2013; 54: 2325-2340.

Jandhyala SM, Talukdar R, Subramanyam C, et al. Role of the normal gut microbiota. World J Gastroenterol 2015; 21: 8787-8803.

Johansson ME, Phillipson M, Petersson J, et al. The inner of the two Muc2 mucin-dependent mucus layers in colon is devoid of bacteria. Proc Natl Acad Sci U S A 2008; 105: 15064-15069.

Kim YS, Ho SB. Intestinal goblet cells and mucins in health and disease: recent insights and progress. Curr Gastroenterol Rep 2010; 12: 319-330.

Van der Sluis M, De Koning BA, et al. Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection. Gastroenterology 2006; 131: 117-129.

Johansson ME, Larsson JM, Hansson GC. The two mucus layers of colon are organized by the MUC2 mucin, whereas the outer layer is a legislator of host-microbial interactions. Proc Natl Acad Sci U S A 2011; 108 Suppl 1: 4659-4665.

Littman DR, Rudensky AY. Th17 and regulatory T cells in mediating and restraining inflammation. Cell 2010; 140: 845-858.

Zhang YZ, Li YY. Inflammatory bowel disease: pathogenesis. World J Gastroenterol 2014; 20: 91-99.

Tan TG, Sefik E, Geva-Zatorsky N, et al. Identifying spe- cies of symbiont bacteria from the human gut that, alone, can induce intestinal Th17 cells in mice. Proc Natl Acad Sci U S A 2016; 113: E8141-E8150.

Mazmanian SK. Gut Immune Balance Is as Easy as S-F-B. Immunity 2009; 31: 536-538.

Vaishnava S, Yamamoto M, Severson KM, et al. The antibacterial lectin RegIIIgamma promotes the spatial seg- regation of microbiota and host in the intestine. Science 2011; 334: 255-258.

Taskiran EZ, Cetinkaya A, Balci-Peynircioglu B, et al. The effect of colchicine on pyrin and pyrin interacting proteins. J Cell Biochem 2012; 113: 3536-3546.

Masters SL, Simon A, Aksentijevich I, et al. Horror auto- inflammaticus: the molecular pathophysiology of auto- inflammatory disease (*). Annu Rev Immunol 2009; 27: 621-668.

Z.A. K. Alterations in gut microbiota composition in famil- ial Mediterranean fever. National Academy of Sciences of Armenia, Reports 2008; 106: 374-380.

Khachatryan ZA, Ktsoyan ZA, Manukyan GP, et al. Predominant role of host genetics in controlling the com- position of gut microbiota. PLoS One 2008; 3: e3064.

Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature 2011; 474: 307-317.

Zamani S, Hesam Shariati S, Zali MR, et al. Detection of en- terotoxigenic Bacteroides fragilis in patients with ulcer- ative colitis. Gut Pathog 2017; 9: 53.

Gevers D, Kugathasan S, Denson LA, et al. The treat- ment-naive microbiome in new-onset Crohn’s disease. Cell Host Microbe 2014; 15: 382-392.

Morgan XC, Tickle TL, Sokol H, et al. Dysfunction of the in- testinal microbiome in inflammatory bowel disease and treatment. Genome Biol 2012; 13: R79.

Darfeuille-Michaud A, Boudeau J, Bulois P, et al. High prevalence of adherent-invasive Escherichia coli associat- ed with ileal mucosa in Crohn’s disease. Gastroenterology 2004; 127: 412-421.

Kang S, Denman SE, Morrison M, et al. Dysbiosis of fecal microbiota in Crohn’s disease patients as revealed by a custom phylogenetic microarray. Inflamm Bowel Dis 2010; 16: 2034-2042.

Lule S, Colpak AI, Balci-Peynircioglu B, et al. Behcet Disease serum is immunoreactive to neurofilament medium which share common epitopes to bacterial HSP-65, a putative trigger. J Autoimmun 2017; 84: 87-96.

Consolandi C, Turroni S, Emmi G, et al. Behcet’s syn- drome patients exhibit specific microbiome signature. Autoimmun Rev 2015; 14: 269-276.

Gill T, Asquith M, Rosenbaum JT, et al. The intestinal microbiome in spondyloarthritis. Curr Opin Rheumatol 2015; 27: 319-325.

Bakland G, Nossent HC. Epidemiology of spondyloarthri- tis: a review. Curr Rheumatol Rep 2013; 15: 351.

Manasson J, Scher JU. Spondyloarthritis and the microbiome: new insights from an ancient hypothesis. Curr Rheumatol Rep 2015; 17: 10.

D’Amelio P, Sassi F. Gut Microbiota, Immune System, and Bone. Calcif Tissue Int 2018; 102: 415-425.

Sandhya P, Danda D, Sharma D, et al. Does the buck stop with the bugs?: an overview of microbial dysbiosis in rheumatoid arthritis. Int J Rheum Dis 2016; 19: 8-20.

Pepoyan AZ, Balayan MA, Atrutyunyan NA, et al. [Antibiotic Resistance of Escherichia Coli of the Intestinal Microbiota in Patients with Familial Mediterranean Fever]. Klin Med (Mosk) 2015; 93: 37-39.

Mkrtchyan H, Gibbons S, Heidelberger S, et al. characterisation and identification of acidocin LCHV, an antimicrobial peptide produced by Lactobacillus aci- dophilus n.v. Er 317/402 strain Narine. Int J Antimicrob Agents 2010; 35: 255-260.

Pepoyan AZ, Balayan MH, Manvelyan AM, et al. Lactobacillus acidophilus INMIA 9602 Er-2 strain 317/402 probiotic regulates growth of commensal Escherichia coli in gut microbiota of familial Mediterranean fever disease subjects. Lett Appl Microbiol 2017; 64: 254-260.

Geirnaert A, Calatayud M, Grootaert C, et al. Butyrate- producing bacteria supplemented in vitro to Crohn’s dis- ease patient microbiota increased butyrate production and enhanced intestinal epithelial barrier integrity. Sci Rep 2017; 7: 11450.

Bowman KA, Broussard EK, Surawicz CM. Fecal microbiota transplantation: current clinical efficacy and future pros- pects. Clin Exp Gastroenterol 2015; 8: 285-291.

Petrof EO, Gloor GB, Vanner SJ, et al. Stool substitute trans- plant therapy for the eradication of Clostridium difficile infection: ‘RePOOPulating’ the gut. Microbiome 2013; 1: 3.